Literature DB >> 25805934

Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy.

In Ja Park1, Chang Sik Yu1, Seok-Byung Lim1, Yong Sik Yoon1, Chan Wook Kim1, Tae Won Kim1, Jong Hoon Kim1, Jin Cheon Kim1.   

Abstract

AIM: To evaluate the predictive value of the lymph node (LN) ratio (LNR, number of metastatic LNs/ examined LNs) for recurrence in patients with rectal cancer and to compare its applicability according to preoperative chemoradiotherapy (PCRT).
METHODS: From 2000 to 2009, 967 patients with metastatic LNs after curative resection for locally advanced rectal cancer were identified. Patients were categorized according to PCRT (PCRT vs No PCRT). The cut-off LNR was determined based on the pN1 vs pN2 when the recommended number of LNs was harvested. The 5-year recurrence-free survival (RFS) rates using the Kaplan-Meier method were compared according to p/yp N stage and the LNR in each group.
RESULTS: Among patients with the same p/ypN stage, the 5-year RFS rate differed according to the LNR. In addition, the 5-year RFS rate was significantly different between pN and LNR groups in patients with No PCRT. In PCRT group, however, only LNR was associated with prognosis. On multivariate analysis, both pN and LNR were significant independent prognostic factors for 5-year RFS in the No PCRT group. In the PCRT group, only LNR category was found to be associated with RFS (HR = 2.36, 95%CI: 1.31-3.84, and P = 0.001).
CONCLUSION: The LNR is an important prognostic predictor of RFS in rectal cancer patients especially treated with PCRT. Current pN categories could not discriminate between prognostic groups of RFS after PCRT.

Entities:  

Keywords:  Lymph node ratio; Preoperative chemoradiotherapy; Prognosis; Rectal cancer; pN

Mesh:

Year:  2015        PMID: 25805934      PMCID: PMC4363757          DOI: 10.3748/wjg.v21.i11.3274

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.

Authors:  Richard S Swanson; Carolyn C Compton; Andrew K Stewart; Kirby I Bland
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

4.  Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis.

Authors:  Nancy N Baxter; Arden M Morris; David A Rothenberger; Joel E Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

5.  Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered.

Authors:  N S Goldstein; W Sanford; M Coffey; L J Layfield
Journal:  Am J Clin Pathol       Date:  1996-08       Impact factor: 2.493

6.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

Authors:  Adam C Berger; Elin R Sigurdson; Thomas LeVoyer; Alexandra Hanlon; Robert J Mayer; John S Macdonald; Paul J Catalano; Daniel G Haller
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  What factors affect lymph node yield in surgery for rectal cancer?

Authors:  C C Thorn; N P Woodcock; N Scott; C Verbeke; S B Scott; N S Ambrose
Journal:  Colorectal Dis       Date:  2004-09       Impact factor: 3.788

8.  Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy.

Authors:  B Morcos; B Baker; M Al Masri; H Haddad; S Hashem
Journal:  Eur J Surg Oncol       Date:  2010-01-13       Impact factor: 4.424

9.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

10.  The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients.

Authors:  Alberto Marchet; Simone Mocellin; Alessandro Ambrosi; Paolo Morgagni; Domenico Garcea; Daniele Marrelli; Franco Roviello; Giovanni de Manzoni; Annamaria Minicozzi; Giovanni Natalini; Francesco De Santis; Luca Baiocchi; Arianna Coniglio; Donato Nitti
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

View more
  12 in total

1.  The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.

Authors:  Salem Y Mohamed; Randa Mohamed Kaf; Mona Mostafa Ahmed; Amira Elwan; Hassan R Ashour; Amr Ibrahim
Journal:  J Gastrointest Cancer       Date:  2019-12

2.  Log odds of positive lymph nodes is an excellent prognostic factor for patients with rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Tianlei Xu; Lin Zhang; Liang Yu; Yuelu Zhu; Hui Fang; Bo Chen; Haizeng Zhang
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yi Li; Ji Wang; Xiaowei Ma; Li Tan; Yanli Yan; Chaofan Xue; Beina Hui; Rui Liu; Hailin Ma; Juan Ren
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

4.  Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Yaqi Wang; Menglong Zhou; Jianing Yang; Xiaoyang Sun; Wei Zou; Zhiyuan Zhang; Jing Zhang; Lijun Shen; Lifeng Yang; Zhen Zhang
Journal:  Cancer Med       Date:  2019-06-28       Impact factor: 4.452

5.  Comparison of Different Lymph Node Staging Systems in Patients With Resectable Colorectal Cancer.

Authors:  Jun-Peng Pei; Chun-Dong Zhang; Yu-Chen Fan; Dong-Qiu Dai
Journal:  Front Oncol       Date:  2019-01-15       Impact factor: 6.244

6.  Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR.

Authors:  Jung Soo Pyo; Joo Heon Kim; Seung Yun Lee; Tae Hwa Baek; Dong Wook Kang
Journal:  Medicina (Kaunas)       Date:  2019-10-04       Impact factor: 2.430

7.  Prognostic Implication of Metastatic Lymph Node Ratio in Colorectal Cancers: Comparison Depending on Tumor Location.

Authors:  Jung-Soo Pyo; Young-Min Shin; Dong-Wook Kang
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

8.  Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision.

Authors:  Zhi-Gui Zuo; Xiu-Feng Zhang; Hao Wang; Qi-Zhi Liu; Xing-Zhao Ye; Chang Xu; Xiang-Bin Wu; Jian-Hui Cai; Zhen-Hua Zhou; Jin-Lei Li; Hua-Yu Song; Zu-Qiang Luo; Peng Li; Shi-Chang Ni; Lei Jiang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Extranodal extension status is a powerful prognostic factor in stage III colorectal cancer.

Authors:  Chan Wook Kim; Jihun Kim; Seung-Seop Yeom; Jong Lyul Lee; Yong Sik Yoon; In Ja Park; Seok-Byung Lim; Seunghee Baek; Chang Sik Yu; Jin Cheon Kim
Journal:  Oncotarget       Date:  2017-05-26

10.  Lymph Node Ratio as a Prognostic Marker in Rectal Cancer Survival: A Systematic Review and Meta-Analysis.

Authors:  Uday Karjol; Pavan Jonnada; Ajay Chandranath; Sushma Cherukuru
Journal:  Cureus       Date:  2020-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.